Paper Details

  1. Home
  2. Paper Details

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Author: AhnMyung-Ju, BesseBenjamin, BlackhallFiona, CamidgeD Ross, CrinóLucio, De PasTommaso, HirshVera, IyerShrividya, JännePasi A, KimDong-Wan, MokTony, Moro-SibilotDenis, NakagawaKazuhiko, O'ByrneKenneth J, PolliAnna, RielyGregory J, SetoTakashi, ShawAlice T, SolomonBenjamin J, TassellVanessa, ThomasMichael, WilnerKeith D, WuYi-Long

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates whether crizotinib, an oral tyrosine kinase inhibitor targeting ALK, is superior to standard chemotherapy in patients with ALK rearrangements.
Paper Details　
Original Abstract of the Article :
In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unk...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1214886

データ提供：米国国立医学図書館（NLM）

Crizotinib vs. Chemotherapy for Advanced ALK-Positive Lung Cancer

The desert of lung cancer research is vast and challenging, with scientists searching for effective treatments for this devastating disease. This study, like a research caravan seeking a new path to conquer this formidable foe, explores the efficacy of crizotinib, a tyrosine kinase inhibitor, compared to standard chemotherapy for advanced ALK-positive lung cancer.

The study, a beacon of hope in the desert of lung cancer research, sets out to determine whether crizotinib, like a potent weapon against the harsh desert environment, offers a superior treatment option for patients with ALK-positive lung cancer. The results, like a clear oasis in the desert, could revolutionize the treatment landscape for this specific type of lung cancer.

Crizotinib: A Potential Game-Changer for ALK-Positive Lung Cancer

This study, a testament to the ongoing search for more effective treatments for lung cancer, highlights the potential of crizotinib as a promising therapy for patients with ALK-positive lung cancer. The results, like a well-worn caravan trail, offer a new direction for clinicians in treating this challenging disease.

Living with Lung Cancer: A Journey of Hope and Resilience

If you're navigating the desert of lung cancer, remember that there is hope. Crizotinib, like a sturdy camel, can help you navigate the challenging terrain of this disease. Seek guidance from your oncologist to discuss personalized treatment options that are best suited for your individual needs.

Dr. Camel's Conclusion

This study, like a well-stocked caravan, provides valuable insights into the potential of crizotinib as a promising treatment option for advanced ALK-positive lung cancer. The results underscore the importance of ongoing research in this field, paving the way for more effective and personalized treatments for patients facing this formidable foe.

Date :
  1. Date Completed 2013-06-28
  2. Date Revised 2022-04-20
Further Info :

Pubmed ID

23724913

DOI: Digital Object Identifier

10.1056/NEJMoa1214886

Related Literature

Article Analysis
・Side Effects of crizotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.